NCI-CONNECT has a number of studies that are open for adult patients with rare central nervous system (CNS) cancers. Check back as we plan to add more.
The project aims to improve our understanding of outcomes and risk factors related to the occurrence of rare CNS cancers. Research shows that certain risk factors may increase a person’s chances of developing cancer. Factors can include exposure to chemicals or other substances, and personal and family medical history. If you take part in this study, you will complete a web-based survey and submit a saliva sample that will be used for genetic testing.
The study objective is to better understand brain and spinal cord tumors and uncover areas for further research. It also aims to connect patients with doctors who can help them manage their illness and give them new treatment options.
The clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with rare CNS tumors.
This clinical trial is investigating the drug marizomib as an effective treatment for people with recurrent ependymoma.
This clinical trial is investigating the immunotherapy drug nivolumab as an effective treatment for people with recurrent IDH-mutant gliomas with and without hypermutator phenotype.
This clinical trial is investigating the drug sunitinib as an effective treatment for people with either a gliosarcoma or primary brain sarcoma.
The clinical trial is investigating the combination of bevacizumab and carboplatin to help control recurrent ependymoma.